Table 1.
Prospective clinical trials of novel cytotoxic agents in EOC
| Study | Agent | Phase | Patients | Platinum sensitive (%) | Response rate (%) | Stable disease (%) | mPFS (months) |
|---|---|---|---|---|---|---|---|
| Sessa et al77 | TR | II | 59, 51 evaluable | 49 | Sensitive: 43; resistant: 7 | Sensitive: 39; resistant: 33 | na |
| Krasner et al78 | TR | II | 147, 141 evaluable | 45 | Sensitive: 29; resistant: 6.3 | Sensitive: 35; resistant: 46 | Sensitive: 5.1; resistant: 2 |
| Del Campo et al79 | TR (2 doses: A/B) | II | 107, 99 evaluable | 100 | A: 29 B: 28 |
A: 52 B: 45 |
na |
| Monk et al80 | TR + PLD | III | 672 | 64 | 27.6 | 7.3 | 7.3 |
| LPD | 18.8 | 5.8 | 5.8 | ||||
| Smit et al81 | PAT | II | 112 | 0 | 6.3 | 44.6 | 2.8 |
| Forster et al82 | PAT + Cb | I b | 37, 21 evaluable | 84 | 62 | 14 | na |
| Colombo et al83 | PAT | III | 829 | 0 | 15.5 | na | 3.7 |
| PLD | 7.9 | 3.7 | |||||
| De Geest et al84 | IXA | II | 51, 49 evaluable | 0 | 14.3 | 40.8 | na |
| Kavanagh et al85 | Cn | II | 36, 34 evaluable | 0 | 15 | 35 | na |
| Rose et al86 | Cn + Cb | III | 247 | 0 | 32 | 3.5 | |
| PLD | 11 | na | 3.5 | ||||
| Vergote et al87 | Cn | III | 461 | 0 | 4 | na | 2.3 |
| PLD or TOP | 11 | 4.4 | |||||
| Kavanagh et al88 | Cn + PLD | II | 39 | 0 | 27.8 | 51.3 | 6 |
| Vergote et al89 | Cn + PLD | III | 125 | 0 | Na | na | 5.6 |
| PLD | 3.7 | ||||||
| Matulonis et al90 | Cb + PEM | II | 45, 44 evaluable | 100 | 51.1 | 31.1 | 7.57 |
| Miller et al91 | PEM high dose | II | 51, 48 evaluable | 0 | 21 | 35 | 2.9 |
| Vergote et al92 | PEM standard | II | 102, 91 evaluable | 0 | 9.3 | 32.6 | 2.8 |
| PEM high dose | 10.4 | 29.2 | 2.8 | ||||
| Sehouli et al93 | Cb + PEM | II | 66, 61 evaluable | 100 | 32.8 | 31.8 | 9.4 |
| Teneriello et al94 | nP | II | 46, 44 evaluable | 100 | 64 | na | 8.5 |
| Coleman et al95 | nP | II | 51, 47 evaluable | 0 | 23 | 36 | 4.5 |
| Tsubamoto et al96 | Iri + Cb | II | 40 | na | Sensitive: 52; resistant: 21 | na | Sensitive: 3.7; resistant: 9.1 |
| Pecorelli et al97 | Gim | II | 69 | 27.5 | 24.6 | 31.9 | na |
Abbreviations: Cb, carboplatin; Cn, canfosfamide; EOC, epithelial ovarian cancer; Gim, gimatecan; Iri, irinotecan; IXA, ixabepilone; na, not available; nP, nab-paclitaxel; PLD, pegylated liposomal doxorubicin; PAT, patupilone; TOP, topotecan; PEM, pemetrexed; TR, trabectedin; mPFS, median progression-free survival.